Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Tocilizumab in amyloidosis-associated kidney disease secondary to inflammatory bowel diseases.

Literature DB >> 23864193

Tocilizumab in amyloidosis-associated kidney disease secondary to inflammatory bowel diseases.

A Cañas-Ventura, E Rodríguez, M Andreu, L Márquez.

Abstract

Entities: Chemical Disease

Mesh：

Year: 2013 PMID： 23864193 DOI： 10.1007/s10620-013-2776-9

Source DB: PubMed Journal: Dig Dis Sci ISSN： 0163-2116 Impact factor: 3.199

× No keyword cloud information.

4 in total

1. Tocilizumab improves cardiac disease in a hemodialysis patient with AA amyloidosis secondary to rheumatoid arthritis.

Authors: Yoshinari Hattori; Yoshifumi Ubara; Keiichi Sumida; Rikako Hiramatsu; Eiko Hasegawa; Masayuki Yamanouchi; Noriko Hayami; Tatsuya Suwabe; Junichi Hoshino; Naoki Sawa; Kenichi Oohashi; Kenmei Takaichi
Journal: Amyloid Date: 2012-01-20 Impact factor: 7.141

2. Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis.

Authors: Daichi Inoue; Hiroshi Arima; Chiharu Kawanami; Yoko Takiuchi; Seiji Nagano; Takaharu Kimura; Sonoko Shimoji; Minako Mori; Sumie Tabata; Soshi Yanagita; Akiko Matsushita; Kenichi Nagai; Yukihiro Imai; Takayuki Takahashi
Journal: Clin Rheumatol Date: 2010-03-15 Impact factor: 2.980

3. Successful use of tocilizumab in a patient with nephrotic syndrome due to a rapidly progressing AA amyloidosis secondary to latent tuberculosis.

Authors: César Magro-Checa; Antonio Navas-Parejo Casado; Elena Borrego-García; Enrique Raya-Álvarez; José Luis Rosales-Alexander; Juan Salvatierra; Trinidad Caballero-Morales; Mercedes Gómez-Morales
Journal: Amyloid Date: 2011-10-12 Impact factor: 7.141

4. Inflammatory bowel disease and systemic AA amyloidosis.

Authors: Prayman T Sattianayagam; Julian D Gillmore; Jennifer H Pinney; Simon D J Gibbs; Ashutosh D Wechalekar; Janet A Gilbertson; Dorota Rowczenio; Philip N Hawkins; Helen J Lachmann
Journal: Dig Dis Sci Date: 2013-01-31 Impact factor: 3.199

4 in total

3 in total

Tocilizumab in amyloidosis-associated kidney disease secondary to inflammatory bowel diseases.

1. Tocilizumab improves cardiac disease in a hemodialysis patient with AA amyloidosis secondary to rheumatoid arthritis.

2. Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis.

3. Successful use of tocilizumab in a patient with nephrotic syndrome due to a rapidly progressing AA amyloidosis secondary to latent tuberculosis.

4. Inflammatory bowel disease and systemic AA amyloidosis.

Review 1. [Dosage and toxicity of antirheumatic drugs in renal insufficiency].

Review 2. Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever.

3. Recurrence of proteinuria after cessation of tocilizumab in patients with AA amyloidosis secondary to FMF.